 Biomarkers, Tumor
"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 4 | 6 | | 2001 | 1 | 4 | 5 | | 2002 | 10 | 6 | 16 | | 2003 | 7 | 2 | 9 | | 2004 | 9 | 8 | 17 | | 2005 | 11 | 10 | 21 | | 2006 | 15 | 13 | 28 | | 2007 | 11 | 6 | 17 | | 2008 | 14 | 19 | 33 | | 2009 | 16 | 21 | 37 | | 2010 | 20 | 14 | 34 | | 2011 | 13 | 10 | 23 | | 2012 | 13 | 16 | 29 | | 2013 | 12 | 26 | 38 | | 2014 | 22 | 17 | 39 | | 2015 | 25 | 22 | 47 | | 2016 | 27 | 27 | 54 | | 2017 | 28 | 24 | 52 | | 2018 | 31 | 27 | 58 | | 2019 | 36 | 35 | 71 | | 2020 | 21 | 28 | 49 | | 2021 | 22 | 27 | 49 | | 2022 | 3 | 28 | 31 | | 2023 | 3 | 10 | 13 | | 2024 | 13 | 31 | 44 | | 2025 | 29 | 29 | 58 | | 2026 | 17 | 10 | 27 |
To return to the timeline, click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Tesch ME, Zheng Y, Guzman-Arocho YD, Collins LC, Heng YJ, Tayob N, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges V, Come SE, Snow C, Winer EP, Mittendorf EA, Partridge AH. Association of Tumor-Infiltrating Lymphocyte Subtypes with Clinical Characteristics and Prognosis in Young Women with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2026 Jun 01; 32(11):2268-2278.
-
Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P, Sturm D, Green AL, Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M, Patel SH, MacNeil M, Vanan MI, Larouche V, Renzi S, Jones J, Perreault S, Mata-Mbemba D, Sangatsuda Y, Yoshimoto K, Lin E, Feddersen C, Cruz O, Pavon-Mengual M, Vizzini O, Zápotocký M, Popovacki A, Klawinski D, Hansford JR, Schlosser MP, Omene E, Alexander KL, Satgunaseelan L, Williams A, Yao K, Ronsley R, Cheng S, Ludlow L, Eisenstat D, Khuong-Quang DA, Tabouret E, André N, Matheson K, Chan A, Lim-Fat MJ, Lapointe S, Cayrol R, Coleman C, Juretic N, McThenia S, Khan S, Wright-Nadkarni M, Salloum R, Galvin RT, Sener U, Hawkins C, Imber BS, Karajannis MA, Jones DTW, Ligon KL, Jabado N, Erker C. Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study. Clin Cancer Res. 2026 Jun 01; 32(11):2243-2254.
-
Sherman ME, Etievant L, Vierkant RA, Winham SJ, Ruddy KJ, Pacheco-Spann L, Wickland DP, Cruz-Reyes N, Stallings-Mann M, Radisky D, Thompson EA, Kachergus JM, Shi J, Rosenberg SM, Snow C, Kirkner GJ, Schapira L, Peppercorn JM, Come S, Borges VF, Warner E, Collins LC, Partridge AH, Pfeiffer RM. Postpartum breast cancer: evidence for a distinct phenotype. J Natl Cancer Inst. 2026 May 01; 118(5):926-936.
-
Wong EYT, Damle SR, Shiu KK, Cohen SA, Lieu CH. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520600.
-
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T. High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2026 Jun; 27(5):96-105.
-
Evangelist M, Wang B, Butrynski JE, Paschold J, Ward PJ, Waterhouse DM, Jotte RM, Ali K, Richards DA, Konduri K, Melnyk A, Owera RS, Hakimian D, Ghaddar H, Lander EM, Robert NJ, Yori JL, Upadhyay V, Spigel DR, Johnson ML. Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices. JCO Precis Oncol. 2026 Apr; 10(4):e2500832.
-
Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort. Mod Pathol. 2026 Jun; 39(6):101006.
-
Rabban JT, Wolsky RJ, Kayraklioglu N, Davies KD, Aisner DL, Devine WP. Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification. Mod Pathol. 2026 Jun; 39(6):101005.
-
Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD. Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst. 2026 Apr 01; 118(4):746-750.
-
Epeldegui M, Moser C, Choi Y, Borok M, Campbell TB, MacPhail P, Hosseinipour MC, Samaneka W, Nyirenda M, Kosgei J, Busakhala N, Martinez-Maza O, Krown SE. Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):416-423.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|